Heron Neutron Medical Corp (7799.TW) made a stellar debut this week, listing at NT$600 and soaring nearly 29%, overtaking Bora Pharmaceuticals (6472.TW) as Taiwan's new biotech IPO leader.

Founded in 2017, Heron Neutron pioneers Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) — a next-gen precision radiotherapy for recurrent, diffuse, and inoperable cancers.

• Evolved from National Tsing Hua University's nuclear reactor tech into a medical accelerator platform
• Targets recurrent head & neck cancers with short, non-hospitalized treatments & fewer side effects
• Secured 670+ international patents, positioning for global leadership
• Established Taiwan's first clinical BNCT center at CMU Hsinchu Hospital with Hermes-Epitek & CMU support

Chairman Chin-Yung Shu: "BNCT fills the critical gaps left by targeted therapy, immunotherapy, and conventional radiotherapy."

More details: https://bit.ly/v112company1

編輯推薦

• 禾榮AB-BNCT硼中子捕獲療法 腫瘤精準放療新藍海